Novo Nordisk A/S (NYSE:NVO)
| 92.60 Delayed Data As of Jul 30 |  +1.23 / +1.35%Today’s Change | 63.22 Today|||52-Week Range 92.87 | +32.57% Year-to-Date |
Latest NVO News | Press Releases
| Intercept's (ICPT) Q2 Loss Narrower Than Expected, Sales Beat Jul 30 / Zacks.com - Paid Partner Content | Why Is Novo Nordisk Buying a Rare-Disease Candidate? Jul 24 / MotleyFool.com - Paid Partner Content |
| KCS Wealth Advisory Buys iShares Investment Grade Bond Factor ETF, Vanguard Short-Term ... Jul 27 / GuruFocus News - Paid Partner Content |
Today’s Trading
| Previous close | 91.37 |
| Today’s open | 92.67 |
| Day’s range | 92.29 - 92.86 |
| Volume | 724,348 |
| Average volume (3 months) | 889,432 |
| Market cap | $157.4B |
Data as of 3:59pm ET, 07/30/2021
Growth & Valuation
| Earnings growth (last year) | +12.27% |
| Earnings growth (this year) | +6.95% |
| Earnings growth (next 5 years) | +9.34% |
| Revenue growth (last year) | +6.13% |
| P/E ratio | 31.5 |
| Price/Sales | 8.42 |
| Price/Book | 20.15 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| BMYBristol-Myers Squibb | -0.28 | -0.41% |
| AZNAstraZeneca | -0.40 | -0.69% |
| SNYSanofi | +0.05 | +0.10% |
| MRKMerck | -0.08 | -0.10% |
Data as of 4:43pm ET, 07/30/2021
Financials
| Next reporting date | August 5, 2021 |
| EPS forecast (this quarter) | $0.77 |
| Annual revenue (last year) | $19.4B |
| Annual profit (last year) | $6.4B |
| Net profit margin | 33.19% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Bagsværd, Capital Region |
Forecasts
